195812-53-4

Upstream product

• 2408-36-8 lithium cyanide 
• 195812-49-8 trans-N-[2-(4-fluorophenyl)-4,5-dihydro-1-methyl-4,4-bis(trifluoromethyl)-1H-imidazol-5-yl]-N-methyl-4-propylcyclohexanecarboxamide 
• 81659-38-3 α,α-bis(trifluoromethyl)-4,5-bis(4-fluorophenyl)-1-methyl-1H-imidazole-2-methanamine 
• 67589-88-2 trans-4-propylcyclohexanecarbonyl chloride 
• 195812-65-8 2-(4-cyanophenyl)-4,5-dihydro-N,1-dimethyl-4,4-bis(trifluoromethyl)-1H-imidazol-5-amine 
• 139982-01-7 N-[2-(4-cyanophenyl)-4,5-dihydro-1-methyl-4,4-bis(trifluoromethyl)-1H-imidazol-5-yl]-4-fluoro-N-methylbenzamide 
• 139982-02-8 4-Cyano-N-[2-(4-cyano-phenyl)-3-methyl-5,5-bis-trifluoromethyl-4,5-dihydro-3H-imidazol-4-yl]-N-methyl-benzamide 
• 139981-80-9 4-Fluoro-N-[2-(4-fluoro-phenyl)-3-methyl-5,5-bis-trifluoromethyl-4,5-dihydro-3H-imidazol-4-yl]-benzamide 

Relevant academic research and scientific papers

Design, synthesis and structure-activity relationship studies of novel 4,4-bis(trifluoromethyl)imidazolines as acyl-CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents

Novel 4,4-bis(trifluoromethyl)imidazolines have been found to be the potent acyl-CoA cholesterol acyltransferase (ACAT) inhibitors. ACAT is responsible for cholesterol esterification in the intestine, liver, and the arterial wall. These novel imidazolines